Bisoprolol Bausch Health: Uses, Dosage & Side Effects
A highly selective beta-1 blocker for the treatment of stable chronic heart failure, used as the starting dose in combination with standard heart failure therapy
Bisoprolol Bausch Health contains bisoprolol fumarate 1.25 mg, a highly selective beta-1 adrenergic receptor blocker used primarily as the initial starting dose in the treatment of stable chronic heart failure with reduced left ventricular ejection fraction. Bisoprolol is one of only four beta-blockers with proven mortality benefit in heart failure, as demonstrated in the landmark CIBIS-II trial. This low-dose formulation enables the careful, gradual up-titration that is essential when initiating beta-blocker therapy in heart failure patients. Bisoprolol is also widely used at higher doses for the treatment of hypertension and stable angina pectoris, and is included on the WHO Model List of Essential Medicines.
Quick Facts: Bisoprolol Bausch Health
Key Takeaways
- Bisoprolol Bausch Health 1.25 mg is the recommended starting dose for initiating beta-blocker therapy in stable chronic heart failure with reduced ejection fraction, always used alongside ACE inhibitors (or ARBs), diuretics, and optionally cardiac glycosides.
- Bisoprolol is one of the most beta-1 selective beta-blockers available, meaning it primarily affects the heart with minimal impact on the lungs and peripheral vasculature at therapeutic doses.
- The landmark CIBIS-II trial demonstrated a 34% reduction in all-cause mortality with bisoprolol in heart failure patients, establishing it as one of only four beta-blockers with proven survival benefit in this condition.
- Dose titration must be slow and careful — typically doubling the dose no more frequently than every 1–2 weeks, guided by heart rate, blood pressure, and symptom tolerance, up to a maximum of 10 mg once daily.
- Never stop bisoprolol abruptly, as sudden withdrawal can cause rebound tachycardia, worsening heart failure, hypertensive crisis, or angina; the dose must always be tapered gradually under medical supervision.
What Is Bisoprolol Bausch Health and What Is It Used For?
Bisoprolol fumarate belongs to the class of medications known as beta-adrenergic receptor blockers, or beta-blockers. More specifically, bisoprolol is classified as a highly selective beta-1 adrenergic blocker. The adrenergic nervous system uses two main types of beta receptors: beta-1 receptors, which are predominantly found in the heart, and beta-2 receptors, which are found primarily in the lungs, blood vessels, and other smooth muscle tissues. Bisoprolol has approximately 20-fold greater affinity for beta-1 receptors compared to beta-2 receptors, making it one of the most cardioselective beta-blockers in clinical use.
When catecholamines (adrenaline and noradrenaline) bind to beta-1 receptors in the heart, they increase heart rate (chronotropy), the force of heart muscle contraction (inotropy), and the speed of electrical conduction through the heart (dromotropy). By competitively blocking these receptors, bisoprolol reduces heart rate, decreases the force of myocardial contraction, and lowers cardiac output. In the context of heart failure, this might seem counterintuitive — why would you want to further reduce the output of an already failing heart? The answer lies in the neurohormonal model of heart failure.
In chronic heart failure, the body compensates for reduced cardiac output by activating the sympathetic nervous system, resulting in chronically elevated levels of catecholamines. While this initially helps maintain cardiac output, prolonged sympathetic activation becomes toxic to the heart muscle. It causes progressive remodeling (enlargement and shape change) of the left ventricle, increases myocardial oxygen demand, promotes arrhythmias, and accelerates the deterioration of heart function. Beta-blockers like bisoprolol break this vicious cycle by blocking the harmful effects of chronic sympathetic overactivation on the heart, allowing it to recover and remodel in a more favorable direction.
The clinical evidence supporting bisoprolol in heart failure is exceptionally strong. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II), published in The Lancet in 1999, was a landmark randomized, double-blind, placebo-controlled trial that enrolled 2,647 patients with stable chronic heart failure (NYHA class III–IV) and a left ventricular ejection fraction of 35% or less. The trial was stopped early because bisoprolol demonstrated a statistically significant 34% reduction in all-cause mortality compared to placebo (11.8% vs. 17.3%). Bisoprolol also reduced sudden cardiac death by 44% and hospital admissions for heart failure by 20%.
Based on this and subsequent evidence, bisoprolol is recommended as a first-line treatment in heart failure with reduced ejection fraction (HFrEF) by all major international guidelines, including the European Society of Cardiology (ESC) 2023 Guidelines and the American Heart Association/American College of Cardiology (AHA/ACC) 2022 Guidelines. It is one of only four beta-blockers with proven mortality benefit in heart failure, alongside carvedilol, metoprolol succinate (extended release), and nebivolol. Bisoprolol is also included on the World Health Organization (WHO) Model List of Essential Medicines, underscoring its global importance in cardiovascular care.
Beyond heart failure, bisoprolol is widely prescribed at higher doses (typically 5–10 mg daily) for the treatment of hypertension (high blood pressure) and stable angina pectoris (chest pain due to reduced blood flow to the heart). In hypertension, bisoprolol lowers blood pressure by reducing cardiac output and, over time, by decreasing peripheral vascular resistance. In angina, it reduces myocardial oxygen demand by lowering heart rate and contractility, thereby reducing the frequency and severity of anginal episodes, particularly during exertion.
In heart failure, the heart is already struggling and highly dependent on sympathetic drive. Starting a beta-blocker too aggressively can temporarily worsen heart failure symptoms, cause dangerous drops in blood pressure, or provoke severe bradycardia. The 1.25 mg starting dose allows the heart to gradually adapt to reduced sympathetic stimulation. Clinical guidelines universally recommend “start low, go slow” when initiating beta-blocker therapy in heart failure — beginning at 1.25 mg once daily and doubling the dose no more frequently than every 1–2 weeks.
What Should You Know Before Taking Bisoprolol Bausch Health?
Contraindications
Bisoprolol must not be used in patients with any of the following conditions, as it could cause serious or life-threatening harm:
- Hypersensitivity to bisoprolol fumarate or any of the excipients in the formulation
- Acute or decompensated heart failure requiring intravenous inotropic therapy — beta-blockers should only be initiated when heart failure is stabilized
- Cardiogenic shock — a condition in which the heart cannot pump enough blood to meet the body’s needs
- Second or third-degree atrioventricular (AV) block without a functioning pacemaker
- Sick sinus syndrome without a pacemaker
- Sinoatrial block
- Symptomatic bradycardia — heart rate below 60 beats per minute causing symptoms such as dizziness or fainting
- Symptomatic hypotension — systolic blood pressure below 100 mmHg causing symptoms
- Severe bronchial asthma or severe chronic obstructive pulmonary disease (COPD) — while bisoprolol is beta-1 selective, at higher doses it can still affect beta-2 receptors in the lungs
- Severe peripheral arterial occlusive disease or severe Raynaud’s syndrome
- Untreated pheochromocytoma — an adrenal gland tumor that produces excess catecholamines
- Metabolic acidosis
Warnings and Precautions
Bisoprolol should be used with particular caution in the following situations, and your doctor may need to adjust your dose or monitor you more closely:
Heart failure initiation phase: When starting bisoprolol for heart failure, patients must be clinically stable (no signs of acute decompensation) and should ideally be on established therapy with an ACE inhibitor (or ARB), a diuretic, and optionally a cardiac glycoside before beta-blocker therapy is introduced. During the first weeks of treatment and during dose up-titration, temporary worsening of heart failure symptoms, hypotension, or bradycardia may occur. Patients should be monitored closely with regular assessment of blood pressure, heart rate, body weight, and signs of fluid retention.
Diabetes mellitus: Bisoprolol can mask the symptoms of hypoglycemia (low blood sugar), particularly tachycardia (fast heart rate). Patients with diabetes should be advised to monitor their blood glucose more frequently when starting or changing the dose of bisoprolol. While bisoprolol’s beta-1 selectivity means it has less impact on glucose metabolism compared to non-selective beta-blockers, blood glucose levels should still be closely monitored.
Thyroid disorders: Beta-blockers can mask the signs and symptoms of thyrotoxicosis (overactive thyroid), particularly tachycardia. Abrupt withdrawal of bisoprolol in patients with thyrotoxicosis may precipitate a thyroid storm.
Psoriasis: Beta-blockers have been reported to aggravate psoriasis in some patients. The decision to use bisoprolol in patients with psoriasis should weigh the potential benefits against this risk.
Anesthesia and surgery: If bisoprolol needs to be discontinued before surgery, this should be done gradually over at least 48 hours. The anaesthetist should be informed that the patient is taking a beta-blocker, as bisoprolol may interact with certain anesthetic agents.
Abrupt discontinuation of bisoprolol can cause a rebound effect with worsening of heart failure, rebound hypertension, increased heart rate, and potentially life-threatening cardiac arrhythmias or angina attacks. If bisoprolol needs to be stopped, the dose should be reduced gradually over at least two weeks, with the dose halved at weekly intervals, under close medical supervision.
Pregnancy and Breastfeeding
Bisoprolol is generally not recommended during pregnancy unless the potential benefit clearly outweighs the risk to the fetus. Beta-blockers reduce placental blood flow, which may lead to intrauterine growth restriction, premature delivery, or fetal death. Additionally, the newborn may experience adverse effects including hypoglycemia, bradycardia, and respiratory depression. If bisoprolol must be used during pregnancy, the lowest effective dose should be employed, treatment should be discontinued at least 72 hours before the expected delivery date when possible, and the newborn should be closely monitored for 48–72 hours after delivery.
It is not known with certainty whether bisoprolol passes into human breast milk, although animal studies suggest it does. Breastfeeding is therefore not recommended during bisoprolol therapy. If the medication is essential, the physician should discuss the risks and benefits with the patient and consider alternative feeding methods for the infant.
How Does Bisoprolol Bausch Health Interact with Other Drugs?
Drug interactions with bisoprolol are clinically important because many of the patients who take this medication are on complex multi-drug regimens for heart failure and cardiovascular disease. The following table summarizes the most important drug interactions that healthcare providers and patients should be aware of. Some of these combinations are not necessarily contraindicated but require enhanced monitoring and possible dose adjustments.
Major Interactions
| Interacting Drug | Effect | Clinical Recommendation |
|---|---|---|
| Verapamil / Diltiazem | Additive negative effects on heart rate, AV conduction, and contractility; risk of severe bradycardia, heart block, and heart failure | Combination generally not recommended. If unavoidable, requires close cardiac monitoring with ECG and blood pressure checks |
| Clonidine | Risk of rebound hypertensive crisis if clonidine is stopped while on bisoprolol; additive bradycardia | If both drugs need to be discontinued, stop bisoprolol first, then taper clonidine several days later |
| Class I Antiarrhythmics (disopyramide, quinidine, flecainide) | Enhanced negative inotropic and dromotropic effects; prolonged AV conduction; increased risk of heart failure and arrhythmias | Use with caution and under specialist supervision; monitor ECG regularly |
| Monoamine Oxidase Inhibitors (MAOIs) | Enhanced hypotensive effect; potential hypertensive crisis if non-selective MAOIs are combined | Avoid combination with non-selective MAOIs; use MAO-B inhibitors with caution |
Minor Interactions
| Interacting Drug | Effect | Clinical Recommendation |
|---|---|---|
| Digoxin | Additive slowing of heart rate and AV conduction | Monitor heart rate and ECG; commonly used together in heart failure but requires dose adjustment |
| NSAIDs (ibuprofen, naproxen, diclofenac) | May reduce the antihypertensive effect of bisoprolol; NSAIDs can also worsen heart failure and impair renal function | Avoid long-term NSAID use in heart failure patients; use lowest effective dose for shortest duration if needed |
| Insulin / Oral Antidiabetics | Bisoprolol may mask tachycardia as a warning sign of hypoglycemia; may prolong hypoglycemic episodes | Increase blood glucose monitoring frequency; educate patients about non-cardiac signs of hypoglycemia (sweating, tremor, hunger) |
| Amlodipine / Nifedipine (dihydropyridine CCBs) | Additive blood pressure lowering; rarely, may worsen heart failure | Generally safe to combine; monitor blood pressure during initiation |
| Anaesthetic agents | Enhanced hypotensive effect and myocardial depression; reflex tachycardia blunted | Inform the anaesthetist; do not abruptly stop bisoprolol before surgery |
Patients should always inform all healthcare providers, including dentists and surgeons, that they are taking bisoprolol. It is important to discuss any new medications, including over-the-counter drugs and herbal supplements, with a doctor or pharmacist before starting them, as even seemingly innocuous products (such as decongestants containing pseudoephedrine or phenylephrine) can interact with beta-blockers by opposing their blood-pressure-lowering effects.
What Is the Correct Dosage of Bisoprolol Bausch Health?
Adults — Heart Failure
The titration of bisoprolol in heart failure follows a well-established protocol that has been validated in clinical trials. Treatment must be initiated during a clinically stable phase, meaning no signs of acute decompensation such as pulmonary edema or significant fluid retention. The patient should already be on optimal doses of an ACE inhibitor (or ARB if ACE inhibitor is not tolerated), a diuretic, and optionally a cardiac glycoside before bisoprolol is introduced.
| Titration Phase | Daily Dose | Duration | Monitoring |
|---|---|---|---|
| Week 1 | 1.25 mg once daily | 1 week minimum | Heart rate, blood pressure, symptoms daily |
| Week 2 | 2.5 mg once daily | 1 week minimum | Heart rate, blood pressure, weight |
| Week 3 | 3.75 mg once daily | 1 week minimum | Heart rate, blood pressure, weight |
| Weeks 4–7 | 5 mg once daily | 4 weeks minimum | Clinical assessment every 2 weeks |
| Weeks 8–11 | 7.5 mg once daily | 4 weeks minimum | Clinical assessment every 2 weeks |
| Week 12 onwards | 10 mg once daily (target) | Ongoing maintenance | Regular follow-up every 3–6 months |
The titration schedule should be individualized based on patient tolerance. If worsening of heart failure symptoms, symptomatic hypotension (systolic blood pressure below 90–100 mmHg), or excessive bradycardia (heart rate below 50–55 bpm) occur during titration, the dose may need to be temporarily reduced or held at the current level until the patient stabilizes. The target dose of 10 mg once daily should be achieved whenever possible, as the clinical benefit is dose-dependent. However, even lower maintenance doses provide some benefit, and achieving any tolerated dose is better than no beta-blocker therapy.
Hypertension and Angina Pectoris (Higher Dose Formulations)
For hypertension and stable angina, bisoprolol is typically available in 5 mg and 10 mg tablets. The usual starting dose is 5 mg once daily, which may be increased to 10 mg once daily if needed. The maximum recommended dose is 20 mg once daily, although doses above 10 mg rarely provide additional benefit. The 1.25 mg Bisoprolol Bausch Health formulation is not typically used as the primary dosage form for these indications but may be useful for dose tapering purposes.
Children
Bisoprolol is not recommended for use in children and adolescents under 18 years of age due to insufficient clinical data on safety and efficacy in this population. There are limited studies evaluating beta-blockers in pediatric heart failure, and the optimal choice and dosing regimen for children remain under investigation. If a beta-blocker is needed in a pediatric patient, the prescribing physician should consult specialist pediatric cardiology guidelines and use an agent with more established pediatric data.
Elderly Patients
No specific dose adjustment is generally required for elderly patients, provided there is no significant renal or hepatic impairment. However, elderly patients are more susceptible to the effects of beta-blockers, including bradycardia, hypotension, and dizziness. Therefore, a more conservative approach to dose titration may be prudent, with closer monitoring during the initiation phase. For heart failure, the same low-dose titration protocol applies regardless of age.
Renal impairment: For patients with severe renal impairment (creatinine clearance below 20 mL/min) or those on dialysis, the maximum recommended dose is 10 mg once daily, and titration should proceed with particular caution. Mild to moderate renal impairment does not require dose adjustment.
Hepatic impairment: For patients with severe hepatic impairment, the maximum recommended dose is 10 mg once daily, and dose increases should be made very cautiously with careful clinical monitoring. Mild to moderate hepatic impairment does not typically require dose adjustment.
Missed Dose
If you miss a dose of bisoprolol, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule. Never take a double dose to compensate for a missed one. If you miss multiple doses, contact your doctor before resuming treatment, as the medication may need to be re-titrated from a lower dose depending on how long you have gone without taking it.
Overdose
Overdose with bisoprolol can cause severe bradycardia (very slow heart rate), marked hypotension (dangerously low blood pressure), heart block, bronchospasm, acute heart failure, and in severe cases, cardiogenic shock and cardiac arrest. Hypoglycemia may also occur, particularly in children or patients with diabetes.
If a bisoprolol overdose is suspected, call your local emergency number or poison control center immediately. Treatment is supportive and may include atropine for bradycardia, intravenous fluids and vasopressors for hypotension, glucagon infusion (the primary antidote for beta-blocker overdose), intravenous isoprenaline, and in severe cases, temporary cardiac pacing. Do not wait for symptoms to develop before seeking medical attention.
What Are the Side Effects of Bisoprolol Bausch Health?
Like all medications, bisoprolol can cause side effects, although not everybody gets them. The side effects listed below are based on data from clinical trials, post-marketing surveillance, and the approved product information. Many of the side effects are related to the pharmacological mechanism of action (beta-1 blockade) and are therefore predictable and often dose-dependent. Side effects are more likely to occur during the initial titration phase, particularly in heart failure patients, and often diminish as the body adapts to the medication over several weeks.
The following side effect frequency grid uses standard medical frequency categories as defined by the European Medicines Agency (EMA) and the Council for International Organizations of Medical Sciences (CIOMS):
Very Common
Affects more than 1 in 10 people
- Bradycardia (slow heart rate) — particularly in heart failure patients
- Worsening of heart failure (during initiation and titration phase)
- Dizziness
Common
Affects 1 in 10 to 1 in 100 people
- Headache
- Fatigue, tiredness, or asthenia
- Feeling cold or numb in hands and feet (cold extremities)
- Hypotension (low blood pressure), especially postural
- Gastrointestinal symptoms: nausea, vomiting, diarrhea, constipation
- Dizziness or lightheadedness when standing up
Uncommon
Affects 1 in 100 to 1 in 1,000 people
- Sleep disturbances, insomnia
- Depression or depressed mood
- AV conduction disturbances (first or second-degree heart block)
- Bronchospasm in patients with asthma or COPD
- Muscle weakness, muscle cramps
- Erectile dysfunction
- Abnormal liver function tests (elevated transaminases)
Rare
Affects less than 1 in 1,000 people
- Nightmares, hallucinations
- Allergic reactions (skin rash, itching, urticaria)
- Severe allergic reactions (anaphylaxis)
- Elevated triglycerides
- Alopecia (hair loss)
- Psoriasis-like skin reactions or worsening of existing psoriasis
- Hearing disturbances
- Allergic rhinitis
- Reduced tear production (relevant for contact lens wearers)
- Hepatitis with jaundice
It is important to distinguish between expected pharmacological effects and true adverse reactions. For example, a mild reduction in heart rate is an expected and desired therapeutic effect of bisoprolol in heart failure, while symptomatic bradycardia (heart rate below 50 bpm causing dizziness or near-syncope) is an adverse effect that warrants dose reduction. Similarly, a modest reduction in blood pressure is therapeutic, while symptomatic hypotension is adverse.
Most patients tolerate bisoprolol well once the target dose has been reached and maintained. In the CIBIS-II trial, the overall discontinuation rate due to adverse events was only slightly higher in the bisoprolol group compared to placebo, demonstrating a favorable safety-to-efficacy ratio. Patients should be reassured that the benefits of beta-blocker therapy in heart failure (reduced mortality, fewer hospitalizations, improved quality of life) far outweigh the risks of manageable side effects.
Seek urgent medical attention if you experience: heart rate consistently below 50 beats per minute with symptoms such as severe dizziness, fainting, or near-fainting; sudden worsening of shortness of breath, marked ankle swelling, or inability to lie flat (signs of decompensated heart failure); severe wheezing or difficulty breathing (bronchospasm); signs of a severe allergic reaction including facial swelling, difficulty swallowing, or widespread rash; or chest pain at rest (unstable angina).
How Should You Store Bisoprolol Bausch Health?
Proper storage of bisoprolol tablets is essential to maintain their potency and safety throughout the entire period of use. The following guidelines should be followed:
- Temperature: Store at room temperature, not exceeding 25°C (77°F). Do not refrigerate or freeze the tablets.
- Moisture protection: Keep the tablets in their original blister packaging or container until ready for use. Bisoprolol fumarate is stable under normal conditions but can be affected by excessive humidity.
- Light protection: Store in the original carton to protect from light when not in use.
- Child safety: Keep all medications out of the sight and reach of children. Consider using a child-resistant storage location, as accidental ingestion of beta-blockers by children can be particularly dangerous due to the risk of severe bradycardia and hypoglycemia.
- Expiration date: Do not use bisoprolol tablets after the expiration date (EXP) stated on the blister pack and carton. The expiration date refers to the last day of that month.
- Disposal: Do not dispose of medications via household waste or wastewater. Return unused medications to a pharmacy for proper disposal. This protects the environment and prevents accidental exposure.
If you notice any change in the appearance of the tablets, such as discoloration, crumbling, or an unusual odor, do not take them and consult your pharmacist. Damaged or deteriorated tablets may have reduced potency or could potentially be harmful.
What Does Bisoprolol Bausch Health Contain?
Active substance: Each film-coated tablet contains 1.25 mg of bisoprolol fumarate, equivalent to approximately 1.06 mg of bisoprolol base. Bisoprolol fumarate is a white crystalline powder that is freely soluble in water and ethanol. Its molecular formula is (C18H31NO4)2 · C4H4O4, with a molecular weight of 766.96 g/mol for the fumarate salt.
Excipients (inactive ingredients): The tablet core and film coating contain pharmaceutical excipients that serve various purposes in tablet manufacturing. These typically include:
- Tablet core: Microcrystalline cellulose (filler/binder), calcium hydrogen phosphate anhydrous (diluent), croscarmellose sodium (disintegrant to aid tablet breakdown in the stomach), colloidal anhydrous silica (glidant), and magnesium stearate (lubricant).
- Film coating: Hypromellose (film-forming agent), macrogol/polyethylene glycol (plasticizer), titanium dioxide E171 (white colorant and opacifier), and potentially iron oxides (for color differentiation between strengths).
Patients with known allergies to any of these excipients should inform their doctor or pharmacist before starting treatment. The lactose-free nature of many bisoprolol formulations makes them suitable for patients with lactose intolerance, but patients should verify the specific excipient list for their particular product with their pharmacist, as formulations may vary between manufacturers.
Appearance: Bisoprolol Bausch Health 1.25 mg film-coated tablets are typically small, round, and coated. The precise color and markings may vary by manufacturing batch and country of distribution. Always verify that the tablets you receive match the description in the patient information leaflet included with your medication.
Frequently Asked Questions About Bisoprolol Bausch Health
Bisoprolol Bausch Health 1.25 mg is primarily used as the starting dose for treating stable chronic heart failure with reduced left ventricular ejection fraction. It is always used in combination with other heart failure medications, including ACE inhibitors (or ARBs), diuretics, and optionally cardiac glycosides. The low 1.25 mg dose allows for safe initiation of beta-blocker therapy, which is then gradually increased to a target dose of 10 mg daily. Bisoprolol at higher doses is also used for treating hypertension and stable angina pectoris.
The 1.25 mg dose is deliberately low because in heart failure, beta-blocker therapy must be started very cautiously. The failing heart is heavily dependent on sympathetic nervous system stimulation to maintain cardiac output. Starting a beta-blocker too aggressively can temporarily worsen heart failure, cause dangerous drops in blood pressure, or provoke severe bradycardia. The “start low, go slow” approach allows the heart to gradually adapt, and clinical trials have shown that this careful titration approach leads to long-term improvements in heart function and survival.
No, you should never stop taking bisoprolol suddenly without consulting your doctor. Abrupt withdrawal can lead to a dangerous rebound effect, including rapid increase in heart rate, spike in blood pressure, worsening of heart failure, and potentially life-threatening cardiac events such as angina or even heart attack. If bisoprolol needs to be discontinued, the dose should be reduced gradually over at least two weeks, typically halving the dose each week, under close medical supervision.
The most common side effects include bradycardia (slow heart rate), dizziness, headache, fatigue, and cold hands and feet. In heart failure patients, temporary worsening of heart failure symptoms is common during the initial dose-titration phase. These effects are related to the medication’s mechanism of action and are usually dose-dependent. Most side effects improve as the body adjusts to the medication over several weeks. Your doctor can manage these effects by adjusting the titration speed or target dose.
Bisoprolol is generally not recommended during pregnancy unless the potential benefit to the mother clearly outweighs the risk to the fetus. Beta-blockers can reduce placental blood flow and may cause fetal growth restriction, bradycardia, and hypoglycemia in the newborn. If bisoprolol is medically necessary during pregnancy, the lowest effective dose should be used, and the newborn should be monitored for 48–72 hours after delivery for signs of beta-blockade. Women who are pregnant or planning to become pregnant should discuss alternative medications with their doctor.
Bisoprolol is one of the most beta-1 selective beta-blockers available, with approximately 20 times greater affinity for heart (beta-1) receptors than lung and vascular (beta-2) receptors. This high cardioselectivity means it has fewer respiratory side effects compared to non-selective beta-blockers like propranolol. It is one of only four beta-blockers proven to reduce mortality in heart failure (alongside carvedilol, metoprolol succinate, and nebivolol). Its long half-life (10–12 hours) supports once-daily dosing, and its balanced renal/hepatic elimination means it requires less dose adjustment in organ impairment than some alternatives.
References
- CIBIS-II Investigators and Committees. “The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.” The Lancet, 1999; 353(9146): 9–13. One of the landmark trials demonstrating 34% mortality reduction with bisoprolol in heart failure.
- McDonagh TA, Metra M, Adamo M, et al. “2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.” European Heart Journal, 2021; 42(36): 3599–3726. Updated 2023. European Society of Cardiology comprehensive heart failure guidelines.
- Heidenreich PA, Bozkurt B, Aguilar D, et al. “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.” Journal of the American College of Cardiology, 2022; 79(17): e263–e421. American guidelines recommending beta-blockers as foundational therapy in HFrEF.
- European Medicines Agency (EMA). Bisoprolol Summary of Product Characteristics (SmPC). Current approved product information for the European market.
- World Health Organization. WHO Model List of Essential Medicines, 23rd List (2023). Bisoprolol is included as an essential cardiovascular medicine.
- British National Formulary (BNF). Bisoprolol fumarate drug monograph. National Institute for Health and Care Excellence (NICE). Current prescribing information and clinical guidance.
- Willenheimer R, van Veldhuisen DJ, Silke B, et al. “Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III.” Circulation, 2005; 112(16): 2426–2435.
- Lechat P, Packer M, Chalon S, et al. “Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials.” Circulation, 1998; 98(12): 1184–1191.
Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, composed of licensed specialist physicians with expertise in cardiology, internal medicine, and clinical pharmacology. All content follows the GRADE evidence framework and adheres to international guidelines from the ESC, AHA/ACC, WHO, and EMA.
Medical Content
Written by specialist physicians in cardiology and clinical pharmacology with experience in heart failure management and cardiovascular pharmacotherapy
Medical Review
Independently reviewed by the iMedic Medical Review Board according to international medical standards and evidence-based medicine principles
Evidence Assessment
All clinical claims are supported by Level 1A evidence from systematic reviews, meta-analyses, and randomized controlled trials including CIBIS-II
Editorial Standards
Content follows iMedic editorial standards: no commercial funding, no pharmaceutical sponsorship, transparent methodology, and regular updates
Conflict of Interest Statement: The iMedic Medical Editorial Team has no financial relationships with pharmaceutical companies. This content is produced independently and is not sponsored by any manufacturer of bisoprolol or competing products.
Last Medical Review: | Next Scheduled Review: